ProPhase Labs (NASDAQ:PRPH) Stock Rating Upgraded by StockNews.com

ProPhase Labs (NASDAQ:PRPHGet Rating) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

Separately, HC Wainwright increased their target price on ProPhase Labs from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, November 11th.

ProPhase Labs Trading Up 2.1 %

Shares of NASDAQ PRPH opened at $8.84 on Thursday. The stock has a market cap of $143.90 million, a P/E ratio of 4.86 and a beta of -0.26. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.21 and a quick ratio of 3.92. ProPhase Labs has a 1 year low of $6.20 and a 1 year high of $15.25. The firm has a 50-day moving average of $10.02 and a 200 day moving average of $10.99.

ProPhase Labs (NASDAQ:PRPHGet Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.09). The company had revenue of $24.20 million for the quarter, compared to the consensus estimate of $18.85 million. ProPhase Labs had a net margin of 21.58% and a return on equity of 42.50%. As a group, sell-side analysts expect that ProPhase Labs will post 1.09 EPS for the current fiscal year.

Institutional Trading of ProPhase Labs

A number of large investors have recently made changes to their positions in the stock. Ritholtz Wealth Management boosted its holdings in shares of ProPhase Labs by 26.0% in the fourth quarter. Ritholtz Wealth Management now owns 26,044 shares of the company’s stock worth $251,000 after buying an additional 5,368 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of ProPhase Labs by 50.4% during the 3rd quarter. Renaissance Technologies LLC now owns 376,810 shares of the company’s stock worth $4,250,000 after acquiring an additional 126,200 shares during the last quarter. Quadrature Capital Ltd grew its position in shares of ProPhase Labs by 56.5% during the 3rd quarter. Quadrature Capital Ltd now owns 30,490 shares of the company’s stock valued at $345,000 after acquiring an additional 11,003 shares during the period. Keebeck Wealth Management LLC bought a new position in ProPhase Labs in the 3rd quarter worth $226,000. Finally, Navellier & Associates Inc. purchased a new position in ProPhase Labs during the third quarter valued at $454,000. 9.75% of the stock is currently owned by institutional investors.

ProPhase Labs Company Profile

(Get Rating)

ProPhase Labs, Inc is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment.

Recommended Stories

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.